1200 AVENUE OF THE AMERICAS, NEW YORK, X1
Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Announces 1-for-10 Reverse Stock Split
Material disclosure
Retention Bonus Agreement with CEO Daniel Vitt Amid Leadership Transition
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Q1
Amended Annual Report
FY 2024
Q3
Q2
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership